Abstract No. 1784-P

Improvement in Glycemic Control, Lipids and Insulin Sensitivity with the Combination of Chromium Picolinate and Biotin in Type 2 Diabetes Mellitus

Authors: CESAR ALBARRACIN, BURCHAM FUQUA, JEFF GEOHAS, MANLEY FINCH, JAMES R. KOMOROWSKI

Institutions: Corpus Christi, TX; Chicago, IL; Purchase, NY

Results: Recent clinical trials suggest chromium picolinate (CrPic), alone and in combination with biotin, improve insulin sensitivity, glucose and lipid metabolism in type 2 DM (T2DM). This 90-day, randomized, double blinded, placebo controlled multicenter prospective study was designed to evaluate the effects of the combination of CrPic and biotin on HbA1c, fasting plasma glucose (FPG), and lipid profiles in patients with T2DM. Subjects were randomly assigned in a 2:1 ratio to active (600 mcg Cr as CrPic and biotin 2 mg/per day) or placebo. Fasting HbA1c, FPG, lipid profiles, and safety information were collected at baseline and at the end of the study. All analyses were conducted on the intent-to-treat (ITT) population (N=368). ITT was defined as any subject who took at least one dose and had one post baseline HbA1c measurement. ANCOVA was calculated for the change in efficacy parameters with treatment as a factor and the corresponding baseline variable as covariates. Model-adequate least square means and 95% CIs for mean differences between the treatment groups were calculated. Change in HbA1c (p<0.01), total cholesterol (p<0.02), and TG/HDL (p<0.0001) were improved in actives compared to placebo. In the active group but not placebo, an increased effect in lowering HbA1c was seen in subjects with higher baseline levels (>7%, -0.54%±0.08; >8%, -0.73%±0.1; >9%, -1.17%±0.15; >10%, -1.78%±0.22; >11%, -1.96%±0.35). At final visit, FPG levels were lower in active than placebo (159±3 mg/dL vs. 171±5 mg/dL; p<0.03). In subjects with baseline cholesterol >200 mg/dL, total cholesterol (-19.11±4.2 mg/dL vs. ?5.87±5.6 mg/dL; p<0.06) and LDL -C (-21.7±4.5 mg/dL vs. ?8.2±3.7mg/dL; p<0.02) were decreased in actives, not placebo. These results suggest that the combination of CrPic and biotin may benefit individuals with T2DM who are hyperglycemic and have dyslipidemia by reducing the risk factors.


DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.